Crossmark

Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports

Crossref DOI link: https://doi.org/10.1186/s13256-021-02771-z

Published Online: 2021-03-25

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yuda, Junichiro

Yamauchi, Nobuhiko

Kuzume, Ayumi

Guo, Yong-Mei

Sato, Nobue

Minami, Yosuke
License Information

Text and Data Mining valid from 2021-03-25

Version of Record valid from 2021-03-25
More Information

Article History

Received: 2 September 2020

Accepted: 3 March 2021

First Online: 25 March 2021

Declarations

:

: The need for ethical approval was waived by National Cancer Center Hospital East.

: Written informed consent was obtained from the patients for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below